MétaCan
Menu
← Back to cohort

Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy.

2025· article· en· W4410805015 on OpenAlexaff
Daniel Boiarsky, Lingzhi Hong, Alissa J. Cooper, Biagio Ricciuti, Maliazurina B. Saad, Arielle Elkrief, Alessandro Di Federico, Muhammad Aminu, Waree Rinsurongkawong, Jeff Lewis, Don L. Gibbons, Ara A. Vaporciyan, Xiuning Le, J. Jack Lee, John V. Heymach, Jia Wu, Mark M. Awad, Adam J. Schoenfeld, Jianjun Zhang, Natalie I. Vokes

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsCentre Hospitalier de l’Université de Montréal
Fundersnot available
KeywordsMedicineLungOncologyImmune systemCancer researchBasal cellLung cancerCarcinomaPathologyInternal medicineImmunology

Abstract

fetched live from OpenAlex

e20555 Background: Molecular profiling is inconsistently performed in patients with mLUSC as it rarely provides actionable information. Whether it can aid in the selection of ICI based therapy is unknown. Methods: Patients with mLUSC (n=963) who received ICI therapy at 9 academic institutions or as part of 3 clinical trials were identified. Overall response rate (ORR) by RECIST 1.1 and clinical progression-free survival (PFS) were the primary outcomes. Propensity matching on age, smoking history, ECOG, sex and PDL1 among previously untreated patients was performed to compare outcomes in patients treated with ICIs alone (ICI-mono) or in combination with chemotherapy (ICI-chemo). Among patients with complete clinico-genomic annotation, including coverage of KEAP1 (n=248), we trained logistic regression (LR), random forest (RF), and gradient boosting (GB) models to predict response. An 80/20 split was used to separate the training and testing cohorts and hyperparameters were optimized for area under the receiver operating characteristic curve (AUROC). Coefficients of the LR model were interrogated to identify predictors of response. The AACR GENIE LUSC cohort (n=2618) was analyzed to assess the prognostic effects of genomic biomarkers. Results: Among propensity matched patients, there was no difference in ORR (ORR: 29 vs 29, p=1.0) or PFS (HR=0.90, p=0.72) between patients who received ICI-chemo versus ICI-mono. Integrating clinical and molecular data improved on PDL1 in predicting response to ICI therapy (AUROC, LR: 0.73, RF: 0.78, GB: 0.69, LR with PDL1 only: 0.70). Top features predictive of response were ICI-chemo, PDL1, sex, and KDM6A , NFE2L2 / KEAP1 , and TP53 alterations; top features predictive of non-response were prior treatment, KRAS and DNMT3A alterations. Among previously untreated patients, improved outcomes were observed in those with vs without KDM6A (n: 13 vs 185; ORR: 85 vs 42, p=0.0032; PFS: HR=0.50, p=0.064) and NFE2L2 / KEAP1 alterations (n: 45 vs 145; ORR: 60 vs 39, p=0.017; PFS: HR=0.60, p=0.0084), while those with vs without KRAS alterations trended towards decreased response rates and PFS (n: 31 vs 274; ORR: 26 vs 43, p=0.083; PFS: HR=1.40, p=0.088). There was no difference in outcomes among patients with KRAS alterations who received ICI-mono vs ICI-chemo. In the GENIE cohort, 4.5% of patients harbored KRAS mutations, which was associated with decreased overall survival (HR=1.5, p=0.0015) as compared to wild-type KRAS . Conclusions: Molecular profiling identified predictors of response to ICI therapy in patients with mLUSC. KDM6A and KEAP1 / NFE2L2 alterations were predictive of response to ICI therapy and may identify patients who could be spared chemotherapy, while KRAS alterations were predictive of non-response and poor prognosis and may identify patients who would benefit from novel treatment strategies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.409
Teacher spread0.369 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→